John Harry Cross Iii.

Chief Financial Officer, Sonnet BioTherapeutics Holdings, Inc.

Companies

Senti Biosciences Holdings, Inc.Chief financial officer Mar 11, 2025 to now¹
Sonnet BioTherapeutics Holdings, Inc.Chief financial officer Apr 3, 2020 to Jul 15, 2025²

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Sonnet BioTherapeutics Holdings, Inc.1,588 shares³Dec 11, 2023

As of each latest filing. The line shows shares held over time.

Recent filings

Dec 11, 2023Granted 1,452 shares of Sonnet BioTherapeutics Holdings, Inc.³
Feb 6, 2023Shares withheld for tax 1,960 shares at $1.06 of Sonnet BioTherapeutics Holdings, Inc.⁴
Dec 14, 2022Granted 15,519 shares of Sonnet BioTherapeutics Holdings, Inc.⁵
Dec 15, 2021Granted 66,951 shares of Sonnet BioTherapeutics Holdings, Inc.⁶

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARSenti Biosciences Holdings, Inc., Chief financial officer
2
SEC EDGARSonnet BioTherapeutics Holdings, Inc., Chief financial officer
3
SEC EDGARSonnet BioTherapeutics Holdings, Inc. shares after the filing of Dec 11, 2023
4
SEC EDGARForm 4 filed Feb 17, 2023
5
SEC EDGARForm 4 filed Dec 22, 2022
6
SEC EDGARForm 4 filed Apr 8, 2022